Why Did Mankind Pharma Limited (MANKIND) Share Price Rise 1.73% Today?
Price Performance Summary
Key Reasons for Today's Rise
Mankind Pharma Limited (MANKIND) shares rose 1.73% on 18 May 2026, closing at ₹2504.90. Today's news shows: ETFs Investing in Mankind Pharma Ltd. Stocks - TradingView. Volume today was 11.2L shares, 1.0x the 30-day average — reflecting moderate participation. Sector performance data unavailable, with the stock outperforming its sector. Investors should monitor follow-up volume and any further news in coming sessions to confirm the trend.
Sector & Market Context
Mankind Pharma Limited operates in the Pharmaceuticals sector. Tracking sector peers and the broader index helps determine whether the move is company-specific or part of a wider trend.
Latest News on Mankind Pharma Limited
Showing news from last 48 hours
ETFs Investing in Mankind Pharma Ltd. Stocks - TradingView
ETFs Investing in Mankind Pharma Ltd. Stocks TradingView
Frequently Asked Questions About Mankind Pharma Limited
Why did Mankind Pharma Limited share price rise today?
Mankind Pharma Limited (MANKIND) rose 1.73% on 18 May 2026 due to ETFs Investing in Mankind Pharma Ltd. Stocks - TradingView. Trading volume was 11.2L shares.
What is Mankind Pharma Limited's 52-week high and low?
52-week high/low data is not available for Mankind Pharma Limited at this time.
Is Mankind Pharma Limited a good stock to watch after today's move?
Today's 1.7% rise in MANKIND on 11.2L volume is worth tracking. Investors should monitor follow-through price action and upcoming corporate announcements. This is not financial advice — please consult a SEBI-registered advisor before investing.
Disclaimer: NiftyPulse360 is not a SEBI-registered investment advisor. The information above is for educational purposes only and should not be construed as financial advice. Always consult a qualified advisor before making investment decisions.
💼 Expert View
Analyst ratings and broker views for Mankind Pharma Limitedare tracked across major brokerages including Motilal Oswal, ICICI Securities, and HDFC Securities. Investors should consider the consensus target price, upcoming earnings calendar, and any analyst upgrade/downgrade actions when evaluating today's rally. Compare with sector peers LAURUSLABS, SUNPHARMA, BIOCON for relative strength analysis.
Note: NiftyPulse360 does not provide buy/sell recommendations. Consult a SEBI-registered investment advisor before making decisions.